PRESS RELEASES

Year
December 16 | 2019
RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices
December 11 | 2019
RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights
December 10 | 2019
RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors
December 04 | 2019
RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer
December 04 | 2019
RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer
December 03 | 2019
RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia
October 30 | 2019
RAPT Therapeutics Announces Pricing of Initial Public Offering
October 23 | 2019
RAPT Therapeutics Announces Initiation of First-in-Human Phase 1 Study of RPT193
October 22 | 2019
RAPT Therapeutics Strengthens Board with Addition of Veteran Biotechnology Executive Wendye Robbins, M.D.
October 21 | 2019
RAPT Therapeutics Strengthens Board with Addition of Veteran Biotechnology Executive Wendye Robbins, M.D.
July 08 | 2019
RAPT Therapeutics Announces Promotion of Key Research and Development Senior Leaders
July 08 | 2019
RAPT Therapeutics Announces the Appointment of Emma Guttman-Yassky, M.D., Ph.D., a Leading Expert in the Field of Inflammatory Skin Diseases, to its Scientific Advisory Board
June 18 | 2019
RAPT Therapeutics Completes $37 Million Series C Extension
May 24 | 2019
FLX Bio Announces Name Change to RAPT Therapeutics
May 20 | 2019
Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical Study
May 13 | 2019
FLX Bio Highlights Preclinical Atopic Dermatitis and Asthma Data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
March 05 | 2019
FLX Bio to Present at Cowen and Company 39th Annual Health Care Conference
January 02 | 2019
FLX Bio to Present at 37th Annual J.P. Morgan Healthcare Conference